AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
156.90
-2.99 (-1.87%)
At close: 4:00PM EDT

156.89 -0.01 (-0.01%)
After hours: 6:18PM EDT

Stock chart is not supported by your current browser
Previous Close159.89
Open160.46
Bid155.46 x 100
Ask159.00 x 100
Day's Range155.73 - 160.92
52 Week Range142.81 - 256.80
Volume2,364,281
Avg. Volume3,307,780
Market Cap51.398B
Beta1.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.88 (1.73%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • U.S. Supreme Court upholds legality of patent review process
    Reuters3 hours ago

    U.S. Supreme Court upholds legality of patent review process

    The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc (OIS.N), a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).

  • Reuters10 hours ago

    U.S. Supreme Court upholds legality of patent review process

    The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc, a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).

  • Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
    Zacks10 hours ago

    Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

    While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

  • Rival Botox Maker Says Patients Can't Wait for It to Hit
    Bloombergyesterday

    Rival Botox Maker Says Patients Can't Wait for It to Hit

    Patients are already clamoring for “the longer acting Botox,” a not-yet approved treatment from Revance Therapeutics, CEO Dan Browne told Bloomberg News in an interview Friday. The launch won’t happen for another two years or so, and while many patients want more time looking younger, doctors are looking for a longer acting product for therapeutic goals. "People underestimate the power of this data,” Browne said, he’s expecting it to be a “major de-risking event” for Revance when results from the study, known as “Sakura” read out later this year.

  • The Wall Street Journal4 days ago

    [$$] Takeda Increases Takeover Proposal for Drug Rival Shire

    Japan’s Takeda said it had made a sweetened proposal to buy Shire after its three previous bids for the rival drugmaker that has drawn broader interest across the sector were rejected.

  • Moody's4 days ago

    Allergan Finance, LLC -- Moody's: Allergan's strategic review increases event risk

    Moody's Investors Service commented that Allergan's ongoing strategic review of potential actions that would create shareholder value raises event risk that financial leverage could increase. There is no impact on the Baa3 ratings on rated subsidiaries including Allergan, Inc. and Allergan Funding SCS, or on the stable rating outlook. For additional information please see Moody's Issuer Comment on Allergan plc available on www.moodys.com.

  • Investopedia4 days ago

    Allergan Declines to Bid on Shire

    Botox maker Allergan said it will no longer consider bidding for Shire.

  • Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
    Zacks4 days ago

    Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

    Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

  • Financial Times5 days ago

    [$$] Shire shares down 3.7% after Allergan rules out bid

    Allergan had made it known that it had contemplated an offer but then decided against it, which sent Shire’s share price down at 3,823 pence from yesterday’s close at 3,831 pence. Takeda shares fell by 4.67 per cent. Shire on Friday confirmed that Allergan had backed away.

  • The Wall Street Journal5 days ago

    [$$] Fast-Growing Shire Had Pharmaceutical Rivals in a Takeover Frenzy

    Drugmaker Shire rebuffed a takeover bid from rival Takeda Pharmaceutical, then Allergan took a look.

  • Allergan Will Not Make Offer for Shire
    Bloomberg5 days ago

    Allergan Will Not Make Offer for Shire

    In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire. Bloomberg's Lisa Du reports on "Bloomberg Daybreak: Asia." ...

  • Shire to World: Let the Bidding Begin
    Motley Fool5 days ago

    Shire to World: Let the Bidding Begin

    Takeda's made three offers to acquire Shire in the past month. Now a new bidder is emerging for the U.K. biopharma.

  • Financial Times5 days ago

    [$$] Best of Lex: your weekly round-up

    Dear readers, This week the Financial Times described the world’s smallest-ever chemistry experiment : the creation of a molecule from two single atoms. What made this achievement even more remarkable ...

  • Reuters5 days ago

    PRESS DIGEST- Financial Times - April 20

    - Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".

  • Reuters5 days ago

    PRESS DIGEST- Financial Times - April 20

    - Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".

  • Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed
    Investor's Business Daily5 days ago

    Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed

    In a rapid turnaround, Allergan said late Thursday it doesn't intend to bid on Shire — leaving thrice-rebuffed Takeda Pharmaceuticals alone in the race for the rare disease drugmaker.

  • Why Is Allergan (AGN) Stock Falling Today?
    Zacks5 days ago

    Why Is Allergan (AGN) Stock Falling Today?

    Allergan (AGN) shares have fallen 5.8% on the day, while Shire plc (SHPG) is up 3.4% so far. These fluctuations come in light of a $50 billion dollar acquisition deal for Shire that is now taking a competitive turn.

  • Allergan Does Not Intend to Make Offer for Shire
    Bloomberg5 days ago

    Allergan Does Not Intend to Make Offer for Shire

    Bloomberg's Drew Armstrong discusses the latest on Allergan, which says they not intend to make an offer for Shire. He speaks with Lisa Abramowicz and Julia Chatterley on "Bloomberg Markets." ...

  • MarketWatch5 days ago

    Blink and you missed it: Allergan doesn't plan to make a Shire bid

    Capping a day of high acquisition drama, Allergan PLC has said it does not plan to make a bid for drugmaker Shire -- mere hours after saying it was considering such a bid. A play for Shire would have pitted Allergan against drugmaker Takeda Pharmaceutical Co. Ltd. , which had its about $60 billion bid for Shire rejected but has continued negotiations. Many Wall Street analysts viewed the potential Allergan-Shire deal poorly.

  • Benzinga5 days ago

    CNBC: Allergan-Shire Deal Is DOA

    Allergan plc (NYSE: AGN ) stock was volatile Thursday after CNBC reported the firm will not pursue a Shire PLC (ADR) (NASDAQ: SHPG ) takeover, citing sources.  The Irish pharmaceutical had published a ...

  • Reuters5 days ago

    Shire rejects $63 billion Takeda bid as Allergan drops pursuit

    NEW YORK/LONDON (Reuters) - Rare disease drug maker Shire Plc (SHP.L) said on Thursday it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd , while Allergan Plc (AGN.N) reversed course on pursuing a rival bid. An acquisition of Shire by Takeda would be by far the biggest acquisition of a drug company year-to-date. Botox-maker Allergan confirmed on Thursday it was considering an offer for Shire after Reuters reported on its interest, sending its shares down 7 percent.

  • Allergan Weighing Shire Bid Has Investors Worried About Deja Vu
    Bloomberg5 days ago

    Allergan Weighing Shire Bid Has Investors Worried About Deja Vu

    Allergan Plc investors have been waiting for the drugmaker to make a bold move after the shares took a beating over the past year, but a potential bid for Shire Plc may not be the deal they wanted.

  • Japan's Takeda takeover bid causes investor headache
    Reuters Videos5 days ago

    Japan's Takeda takeover bid causes investor headache

    Takeda Pharmaceutical shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make after London-listed drugmaker Shire rejected its latest $63 bln bid. As Kate King reports, Botox-maker Allergan has also pulled out of the bidding battle.

  • Allergan Will Not Make Offer for Shire
    Bloomberg Video5 days ago

    Allergan Will Not Make Offer for Shire

    Apr.19 -- In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire. Bloomberg's Lisa Du reports on "Bloomberg Daybreak: Asia."

  • CEO of Botox competitor: 'With scale,' we think we'll hav...
    CNBC Videos5 days ago

    CEO of Botox competitor: 'With scale,' we think we'll hav...

    Jim Cramer hears from Revance Therapeutics co-founder, President and CEO Dan Browne about his biotechnology therapy that competes with Allergan's Botox.